Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy MacroGenics stock

Learn how to easily invest in MacroGenics stock.

MacroGenics Inc is a biotechnology business based in the US. MacroGenics shares (MGNX) are listed on the NASDAQ and all prices are listed in US Dollars. MacroGenics employs 427 staff and has a trailing 12-month revenue of around $66.9 million.

How to buy shares in MacroGenics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – MGNX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

MacroGenics stock price (NASDAQ: MGNX)

Use our graph to track the performance of MGNX stocks over time.

MacroGenics shares at a glance

Information last updated 2022-09-18.
Latest market close$3.04
52-week range$2.13 - $22.78
50-day moving average $3.97
200-day moving average $7.95
Wall St. target price$10.72
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-3.56

Buy MacroGenics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 7 of 7
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$0
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
$0
$0
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
$0
$0
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy MacroGenics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

MacroGenics price performance over time

Historical closes compared with the close of $3.04 from 2022-09-23

1 week (2022-09-16) -11.88%
1 month (2022-08-25) -22.45%
3 months (2022-06-24) -8.98%
6 months (2022-03-24) -66.88%
1 year (2021-09-24) -84.60%
2 years (2020-09-25) -87.85%
3 years (2019-09-25) 12.97
5 years (2017-09-22) 17.05

Is MacroGenics stock undervalued or overvalued?

Valuing MacroGenics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of MacroGenics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

MacroGenics's PEG ratio

MacroGenics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.01. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into MacroGenics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

MacroGenics financials

Revenue TTM $66.9 million
Gross profit TTM $-139,781,000
Return on assets TTM -42.64%
Return on equity TTM -94.75%
Profit margin 0%
Book value $2.32
Market capitalisation $212 million

TTM: trailing 12 months

MacroGenics share dividends

We're not expecting MacroGenics to pay a dividend over the next 12 months.

MacroGenics share price volatility

Over the last 12 months, MacroGenics's shares have ranged in value from as little as $2.13 up to $22.78. A popular way to gauge a stock's volatility is its "beta".

MGNX.US volatility(beta: 1.94)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while MacroGenics's is 1.9365. This would suggest that MacroGenics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

MacroGenics overview

MacroGenics, Inc. , a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc.

Frequently asked questions

What percentage of MacroGenics is owned by insiders or institutions?
Currently 2.598% of MacroGenics shares are held by insiders and 104.011% by institutions.
How many people work for MacroGenics?
Latest data suggests 427 work at MacroGenics.
When does the fiscal year end for MacroGenics?
MacroGenics's fiscal year ends in December.
Where is MacroGenics based?
MacroGenics's address is: 9704 Medical Center Drive, Rockville, MD, United States, 20850
What is MacroGenics's ISIN number?
MacroGenics's international securities identification number is: US5560991094
What is MacroGenics's CUSIP number?
MacroGenics's Committee on Uniform Securities Identification Procedures number is: 556099109

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site